$1.76 -0.18 (-9.28%) Galectin Therapeutics Inc - NASDAQ

Aug. 25, 2016 | 10:53 AM
Last Trade: 1.76
Trade Time: Aug 25 10:53 AM Eastern Daylight Time
Change: -0.18 (-9.28%)
Prev Close: 1.94
Open: 1.85
Bid: 1.76
Ask: 1.78
  1. No results found.
  1. Morning Market Losers

    Benzinga | Nov. 20, 2015 | 10:06AM EST
  2. Galectin Therapeutics' Executive Chairman to Discuss Silent Epidemic and Company's Role in Developing Treatments for NASH and Other Diseases at Robins Equity Research Roundup Conference

    Benzinga | Oct. 7, 2015 | 16:09PM EST
  3. Galectin Therapeutics, Inc. Executive Chairman Jim Czirr to Be Interviewed on "The Big Biz ...

    GuruFocus | Oct. 7, 2015 | 00:03AM EST
  4. Benzinga's Top Initiations

    Benzinga | Sep. 21, 2015 | 10:11AM EST
  5. Galectin Therapeutics Announces Start of Phase 2 Clinical Trial with GR-MD-02 in NASH with Advanced Fibrosis

    Benzinga | Sep. 16, 2015 | 07:58AM EST
  6. Mid-Day Market Update: Thursday's Movers, China, Tesla And More

    Benzinga | Aug. 13, 2015 | 13:09PM EST
  7. Morning Market Gainers

    Benzinga | Aug. 13, 2015 | 09:45AM EST
  8. Morning Market Gainers

    Benzinga | Jan. 7, 2015 | 09:38AM EST
  9. Stocks Hitting 52-Week Lows

    Benzinga | Dec. 24, 2014 | 10:12AM EST
  10. MLV & Co Has Positive Outlook On Galectin Therapeutics Inc

    Benzinga | Sep. 16, 2014 | 09:56AM EST
  11. UPDATE: Aegis Capital Downgrades Galectin Therapeutics

    Benzinga | Aug. 1, 2014 | 12:26PM EST
  12. Galectin Issues Statement on Yesterday's Sell Off, Says Attributed To Negative Social Media Posts and Misinterpretation

    Benzinga | Jul. 30, 2014 | 09:09AM EST
  13. Morning Market Losers

    Benzinga | Jul. 29, 2014 | 09:54AM EST
  14. Galectin Offers Results in Preclinical Model of GR-MD-02, Results Show Significant Disease Improvement

    Benzinga | Jun. 23, 2014 | 08:06AM EST
  15. Galectin Therapeutics Completes Enrollment of Second Cohort of Phase 1 Trial of GR-MD-02

    Benzinga | Apr. 23, 2014 | 08:02AM EST
Trading Center